D-二聚体升高且未抗凝可预测重症COVID-19患者肺栓塞
在法国某高COVID-19发病率地区大学医院住院的349例COVID-19患者中,162例因严重临床征象或快速恶化接受CTPA检查,44例(27.2%)确诊肺栓塞。多变量分析显示D-二聚体水平和未使用任何抗凝治疗是CTPA确诊肺栓塞的独立预测因素,D-二聚体cut-off值2590 ng·mL-1预测肺栓塞的AUC为0.88。
要点
- D-二聚体>2590 ng·mL-1与调整后肺栓塞风险增加17倍相关
- 未使用任何抗凝治疗者肺栓塞风险显著升高(OR 4.5)
- D-二聚体每增加一个四分位,肺栓塞风险OR为4.0
核心结论
- D-二聚体升高(>2590 ng·mL-1)和未抗凝治疗可预测因严重临床征象住院的COVID-19患者发生肺栓塞。
研究设计与样本
- 回顾性分析法国某高COVID-19发病率地区大学医院349例住院COVID-19患者,其中162例因严重临床征象或快速恶化接受CTPA检查。
- 多变量分析采用Firth惩罚最大似然估计。
主要发现
- 162例接受CTPA的患者中44例(27.2%)确诊肺栓塞,多数为段性肺栓塞,肺栓塞相关右心室功能障碍发生率为15.9%。
- 多变量分析显示D-二聚体水平(每增加一个四分位OR 4.0,95%CI 2.4-6.7)和未使用任何抗凝治疗(OR 4.5,95%CI 1.1-7.4)是CTPA确诊肺栓塞的仅有两个显著预测因素。
- ROC曲线分析确定D-二聚体cut-off值2590 ng·mL-1预测肺栓塞的AUC为0.88(p<0.001),敏感性83.3%,特异性83.8%。
- D-二聚体>2590 ng·mL-1与调整后肺栓塞风险增加17倍相关。
临床怎么用
- 对因严重临床征象住院的COVID-19患者,可考虑以D-二聚体>2590 ng·mL-1为指导更广泛地使用CTPA筛查肺栓塞。
- 数据支持对重症住院COVID-19患者进行系统性抗凝治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronavirus disease 2019 (COVID-19) may predispose to venous thromboembolism. We determined factors independently associated with computed tomography pulmonary angiography (CTPA)-confirmed pulmonary embolism (PE) in hospitalised severe COVID-19 patients. METHODS: Among all (n=349) patients hospitalised for COVID-19 in a university hospital in a French region with a high rate of COVID-19, we analysed patients who underwent CTPA for clinical signs of severe disease (oxygen saturation measured by pulse oximetry ≤93% or breathing rate ≥30 breaths·min-1) or rapid clinical worsening. Multivariable analysis was performed using Firth penalised maximum likelihood estimates. RESULTS: 162 (46.4%) patients underwent CTPA (mean±sd age 65.6±13.0 years; 67.3% male (95% CI 59.5-75.5%). PE was diagnosed in 44 (27.2%) patients. Most PEs were segmental and the rate of PE-related right ventricular dysfunction was 15.9%. By multivariable analysis, the only two significant predictors of CTPA-confirmed PE were D-dimer level and the lack of any anticoagulant therapy (OR 4.0 (95% CI 2.4-6.7) per additional quartile and OR 4.5 (95% CI 1.1-7.4), respectively). Receiver operating characteristic curve analysis identified a D-dimer cut-off value of 2590 ng·mL-1 to best predict occurrence of PE (area under the curve 0.88, p<0.001, sensitivity 83.3%, specificity 83.8%). D-dimer level >2590 ng·mL-1 was associated with a 17-fold increase in the adjusted risk of PE. CONCLUSION: Elevated D-dimers (>2590 ng·mL-1) and absence of anticoagulant therapy predict PE in hospitalised COVID-19 patients with clinical signs of severity. These data strengthen the evidence base in favour of systematic anticoagulation, and suggest wider use of D-dimer guided CTPA to screen for PE in acutely ill hospitalised patients with COVID-19.
引用
- Mouhat B, Besutti M, Bouiller K, et al. Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients. Eur Respir J. 2020. PMID: 32907890. doi:10.1183/13993003.01811-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。